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Abstract
Thrombotic risk is increased in eosinophil-mediated disorders, and several hypotheses have been proposed to link
eosinophilia and thrombosis. In particular, eosinophils have been described as source of tissue factor (TF), the main initiator
of blood coagulation; however, this aspect is still controversial. This study was aimed to evaluate whether TF expression
varies in eosinophils isolated from normal subjects and patients with different hypereosinophilic conditions. Eosinophils
were immunologically purified from peripheral blood samples of 9 patients with different hypereosinophilic conditions and
9 normal subjects. Western blot analysis and real-time polymerase chain reaction (RT-PCR) were performed to test
eosinophil TF expression. For comparison, TF expression was evaluated in monocytes from blood donors and in human
endothelial (ECV304) and fibroblast (IMR90) cell lines. Western blot analysis revealed a major band of 47,000 corresponding
to native TF in homogenates of purified eosinophils with a higher intensity in the 9 patients than in the 9 controls (p,
0.0001). According to RT-PCR cycle threshold (Ct), TF gene expression was higher in eosinophils from patients than in those
from controls, median (range) 35.10 (19.45–36.50) vs 37.17 (35.33–37.87) (p = 0.002), and was particularly abundant in one
patient with idiopathic hypereosinophilic syndrome and ischemic heart attacks (Ct: 19.45). TF gene expression was
moderate in monocytes, Ct: 31.32 (29.82–33.49) and abundant in endothelial cells, Ct: 28.70 (27.79–29.57) and fibroblasts, Ct:
22.77 (19.22–25.05). Our results indicate that human blood eosinophils contain variable amounts of TF. The higher TF
expression in patients with hypereosinophilic disorders may contribute to increase the thrombotic risk.
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Introduction
Eosinophils are leukocytes involved in host protection against
parasite infection and in allergic reactions [1]. During T-helper 2-
type immune response, they are recruited at sites of inflammation
where they produce an array of cytokines and lipid mediators, and
release toxic granule proteins [2,3]. Thus, they induce and amplify
inflammatory changes and contribute to tissue damage. Besides
these well known functions, several lines of evidence now indicate
eosinophils as multifunctional leukocytes involved in tissue
homeostasis, adaptive immune responses, innate immunity [2–4]
and coagulation [5]. An increase in blood eosinophil number can
occur in several disorders [6] presenting with a wide spectrum of
manifestations, ranging from asymptomatic conditions to multi-
organ involvement [7,8]. In particular, it has been observed that in
eosinophil-mediated disorders there is an increased risk of
thrombosis [9–13], and several hypotheses have been proposed
to link eosinophilia and thrombosis, involving endothelium
damage, platelet activation and coagulation. Endothelial cells
may be damaged by eosinophil peroxidase products. Moreover,
peroxidase and several additional proteins contained in eosinophil
granules, such as eosinophil cationic protein and major basic
protein, can stimulate platelet activation and aggregation [14–18].
Eosinophils express CD40 ligand, which is involved in initiation
and progression of thrombosis through amplification of the
inflammatory network [16]. Finally, it has been shown that
eosinophils store tissue factor (TF), which is mainly embodied
within their specific granules and is exposed upon activation [5].
However, some of these aspects remain controversial because
Sovershaev et al. did not confirm tissue factor expression in highly
purified preparations of human eosinophils [19].
With this background, we evaluated TF expression by
eosinophils isolated from blood samples of normal subjects and
patients with different hypereosinophilic conditions. For this
purpose, western blot analysis and real-time polymerase chain
reaction (RT PCR) for TF were performed. For comparison, TF
expression was also evaluated in cells commonly recognized as
source of TF, i.e. monocytes from blood donors and human
endothelial and fibroblast cell lines.
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Subjects and Methods
Subjects
Nine normal subjects (6 men and 3 women, age range 40–72
years) and 9 patients with different hypereosinophilic conditions (2
with idiopathic hypereosinophilic syndrome, 2 with bullous
pemphigoid, 1 with Churg Strauss syndrome, 2 with eosinophilic
asthma, and 2 with nematodes infestation; 7 men and 2 women,
age range 40–78 years) were studied (Table 1). All the patients
were evaluated in an active phase of their disease, before starting
any systemic treatment aimed at reducing eosinophil number.
Their blood pressure and cholesterol levels were within the normal
range. The two patients with idiopathic hypereosinophilic
syndrome (patients n. 5 and 6 in Table 1) also suffered from
ischemic heart attacks that disappeared after the normalization of
eosinophil count obtained with corticosteroid treatment. Eosino-
phils were isolated from peripheral blood of both patients and
controls. Proteins and RNA from eosinophils were used for
western blot and real-time PCR, respectively.
The study was approved by the local Review Board of Internal
Medicine, Dermatology, Allergy and Clinical Immunology of the
University of Milan, Italy, and all of the subjects gave their written
informed consent.
Eosinophil isolation
Leukocyte suspensions were obtained by dextran sedimentation
of peripheral blood anticoagulated with 3.75% Na2EDTA (Sigma-
Aldrich St Louis, Mo, USA) diluted 1:2 in 0.9% sodium chloride.
Dextran sedimentation (3 g D-Glucose, Sigma-Aldrich St Louis,
Mo, USA; 3 g Dextran T500, Carl Roth Gmbh, Karlsruhe,
Germany) lasted 90 minutes at room temperature. Twenty ml of
leukocyte-enriched plasma were layered over 12 ml of a density
gradient medium (sodium diatrizoate 9.1%; polysaccharide 5.7%;
r= 1.077 g/ml, Fresenius Kabi, Oslo, Norway) in 50 ml conical
tube and centrifuged at 6006g for 20 minutes at 20uC. The cell
pellet containing eosinophils and neutrophils was collected and the
contaminating red cells were eliminated by hypotonic ammonium
chloride lysis solution (155 mM NH4Cl4, 10 mM KHCO3 and
0,1 mM Na2EDTA, Sigma-Aldrich St Louis, Mo, USA) for 10
minutes at 4uC. Contaminating neutrophils were removed using a
magnetic-activated cell sorting system (Miltenyi Biotec Gmbh,
Bergish Gladbach, Germany), containing a cocktail of biotin-
conjugated monoclonal antibodies against CD2, CD14, CD16,
CD19, CD56, CD123 and CD235a (Glycophorin A). Percentage
purification of eosinophils recovered ranged from 95 to 99%, as
assessed by differential count of 500 cells on May Grunwald
Giemsa-stained cytocentrifuge smears (Figure 1). For protein
extraction and western-blot analysis, 107 cells were used in each
experiment. For RNA extraction, 36106 cells were used in each
experiment.
Monocyte isolation
Monocytes were isolated from peripheral blood mononuclear
cells using a monocyte isolation kit from Miltenyi Biotec Gmbh
(Bergish Gladbach, Germany), an indirect magnetic labeling
system. Non-monocytes, such as T cells, NK cells, B cells,
dendritic cells, and basophils, are indirectly magnetically labeled
using a cocktail of biotin-conjugated antibodies and anti-biotin
microbeads. Highly pure unlabeled monocytes are obtained by
depletion of the magnetically labeled cells. For protein extraction
and western-blot analysis, 107 cells were used in each experiment.
For RNA extraction, 106 cells were used for each experiment.
Endothelial cell culture
Human ECV304 endothelial cells, European Collection of Cell
Cultures (ECACC) No. 92091712, were grown in M199 supple-
mented with 10% fetal bovine serum, penicillin 50 U/mL and
Table 1. Demographic and clinical characteristics of patients with hypereosinophilia.
N Age (years) Sex Diagnosis Blood eosinophils (n/ml)
1 71 F Bullous pemphigoid 1680
2 40 M Asthma with eosinophilia 3080
3 78 M Bullous pemphigoid 1620
4 77 F Churg-Strauss syndrome 2140
5 44 M Asthma with eosinophilia 1600
6 55 M Strongyloidiasis 3100
7 48 M Ascariasis 3260
8 69 M Idiopathic hypereosinophilic syndrome 6210
9 63 M Idiopathic hypereosinophilic syndrome 2870
doi:10.1371/journal.pone.0111862.t001
Figure 1. Representative cytocentrifuge smears of two high
purity eosinophil preparations obtained from peripheral blood
samples. May-Gru¨nwald-Giemsa staining, original magnification: X 400
in the upper panels and X 1000 (immersion) in the lower panels.
doi:10.1371/journal.pone.0111862.g001
Tissue Factor Expression by Eosinophils
PLOS ONE | www.plosone.org 2 November 2014 | Volume 9 | Issue 11 | e111862
streptomycin 100 mg/ml at 37uC in humidified air with 5% CO2.
When endothelial cells reached over 90% of the flask, 2 ml of
trypsin 0.02% with EDTA 0.02% (Sigma-Aldrich, St Louis, Mo,
USA) was instilled and left in humidified incubator for 10 minutes.
Five ml of culture medium, supplemented with 10% fetal bovine
serum, were added to cells to neutralize the enzymatic action of
trypsin. For protein extraction and western-blot analysis, 107 cells
were used in each experiment. For RNA extraction, 106 cells were
used for each experiment.
Fibroblast culture
Human IMR-90 fibroblast cells, American Type Culture
Collection (ATCC) No. CCL-186, were grown in 10 ml of
Dulbecco’s Modified Eagle’s medium (DMEM) with 10% fetal
bovine serum (Sigma-Aldrich, St Louis, Mo, USA), penicillin
(100 UI/ml) and streptomycin (100 mg/ml) (Sigma-Aldrich, St
Louis, Mo, USA) at 37uC. Cell cultures were maintained in
humidified incubator at 37uC with 5% CO2, until fibroblasts
reached over 95% of confluence. Then, 2 ml of 0.25% trypsin
with 0.02% EDTA (Sigma-Aldrich, St Louis, Mo, USA) was
instilled in the Petri dish and left in humidified incubator for 10
minutes. Five ml of culture medium, supplemented with 10% fetal
bovine serum, were added to cells to neutralize the enzymatic
action of trypsin. For protein extraction and western-blot analysis,
107 cells were used in each experiment. For RNA extraction, 106
cells were used for each experiment.
Western blot analysis of Tissue Factor
Western blot analysis for TF was performed on cell lysates. Cells
(107) were lysed with 0.5 ml ice cold RIPA (radio-immunoprecip-
itation assay) buffer (Thermo Scientific, Rockford, IL, USA) with
freshly added protease and phosphatase inhibitors. After lysis, total
protein levels were measured using the bicinchoninic acid assay
(Pierce Biotechnology, Thermo Scientific, Rockford, IL, USA).
Equal protein amounts (20 mg) were warmed at 95–98uC with 2-
bmercaptoethanol bromophenol blue buffer (Bio-Rad Laborato-
ries, Hercules, CA, USA), subjected to 11% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), trans-
ferred by electroblotting onto nitrocellulose membranes (What-
mann, Dassel, Germany) and incubated with blocking buffer (free
protein blocking buffer T20, Pierce Biotechnology, Thermo
Scientific, Rockford, IL, USA). As control, recombinant human
TF purified from SF9 cells (Haematologic Technologies Inc,
Essex, VT, USA) was also loaded. Western blotting was performed
with 1:1000 mouse monoclonal anti-TF antibody (2K1 Abcam,
Cambridge, UK) corresponding to the concentration of 1000
ng/ml. Protein loading was controlled by probing the membranes
with 1:10000 monoclonal antibodies against b-actin (AC-74
Sigma-Aldrich, St Louis, MO, USA). Bands were visualized by
incubation of membranes with horseradish peroxidase–conjugated
rabbit anti-mouse secondary antibody (Sigma-Aldrich, St Louis,
MO, USA) and a chemiluminescence-based detection system
(ECL WB GE Healthcare, Amersham, Little Chalfont, UK).
Density of the bands was evaluated by computerized image
analysis (Image Master; Pharmacia, Uppsala, Sweden) and
expressed as the ratio to the density of the band corresponding
to standard recombinant TF. The choice of 2K1 as anti-TF
primary antibody derived from a comparative evaluation with two
other monoclonal antibodies (GMA-320, Upstate, Lake Placid,
NY, USA and 4G4 Abnova, Taipei, Taiwan), as shown below.
Western blot analysis to test the binding of anti-TF
antibodies to TF
Ten microliters of recombinant human TF purified from SF9
cells (Haematologic Technologies Inc, Essex, VT, USA), at the
concentration of 140 ng/ml, were sujected to 11% SDS-PAGE in
three different lanes and transferred by electroblotting onto
nitrocellulose membranes. TF was identified in each lane with
one of the three monoclonal anti-TF antibodies (2K1, 4G4 and
GMA320) and revealed with horseradish peroxidase–conjugated
rabbit anti-mouse secondary antibody.
Immunoassay to test the binding of anti-TF antibodies to
TF
Recombinant human TF purified from SF9 cells (Haematologic
Technologies Inc, Essex, VT, USA) was adsorbed to microtitration
plates by overnight incubation of protein diluted 10 mg/ml in PBS
(phosphate buffered saline) pH 7.4 at 4uC. After block with BSA
(bovine serum albumin) and washing, scalar dilutions of the tested
antibody (from 1000 ng/ml to 10 ng/ml) were incubated 1 hour
at room temperature, and then detected by a peroxidase-
conjugated goat anti-mouse antibody (Sigma-Aldrich, St Louis,
MO, USA).
Real-Time PCR System
For total RNA extraction, isolated cells (106) were treated using
a high pure RNA isolation kit (Roche Diagnostics GmbH,
Mannheim, Germany) according to the manufacturer’s instruc-
tions.
For cDNA construction, 300 ng of total RNA were processed
using a high capacity RNA-to-cDNA kit (Life Technologies,
Carlsbad, CA, USA) for 60 minutes at 37uC and stopping the
reaction at 95uC for 5 minutes.
Real-time amplification was performed as follows: cDNA (1 to
9 ml) was amplified using TaqMan Gene Expression Master Mix
with primers and probes of beta-actin and TF genes (Life
Technologies, Carlsbad, CA, USA), respectively housekeeping
and target. The sequence detection systems consisted in an
Figure 2. Binding of human recombinant tissue factor (TF) by
three commercial anti-TF antibodies (2K1, 4G4 and GMA)
evaluated by western blot (upper panel) and enzyme immu-
noassay (lower panel) methods. Only 2K1 efficiently recognizes TF
with both methods. The last lane of western blotting refers to the size
markers (SM). In enzyme immunoassay experiments, data represent the
mean of three different measurements.
doi:10.1371/journal.pone.0111862.g002
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activation of 2 minutes at 50uC, UNG (Uracil N-Glycosylase) -
UDG (uracil-DNA glycosylase) incubation, 10 minutes at 95uC, 40
cycles at 95uC for 10 seconds each, 1 minute at 60uC (anneal/
extend). The accumulation of fluorescent signal was detected. The
number of cycles required for the fluorescent signal to exceed the
threshold over the background level is defined cycle threshold
[20]. Levels of cycle threshold are inversely proportional to the
amount of target nucleic acid in the sample (i.e. the lower the cycle
threshold level the greater the amount of target nucleic acid in the
sample). A strong positive reaction, indicative of abundant target
nucleic acid in the sample, corresponds to cycle thresholds lower
than 29. Cycle thresholds of 30–37 are positive reactions indicative
of moderate amounts of target nucleic acid. Cycle thresholds of
38–40 are weak reactions indicative of minimal amounts of target
nucleic acid which could represent an environmental contamina-
tion. Moreover, we analysed PCR data of TF considering for each
individual value its beta actin control, and the results were
calculated with the equation: 2DCt = 2(Ct TF- Ct Actin) according to
Zhu et al. [21].
Statistical analysis
Results were expressed as median and [range]. Mann-Whitney
U test for unpaired values was used to assess the statistical
significance of the differences between groups. A P value of ,0.05
was considered statistically significant. Differences in frequencies
of TF expression were evaluated by Chi-square test. All analyses
were performed by the SPSS PC statistical package, version 20.00
(IBM SPSS, Armonk, NY, USA).
Results
Detection of tissue factor in isolated eosinophils
We tested the ability to detect native TF of 3 commercial anti
TF antibodies by both western blot (Figure 2, upper panel) and
enzyme immunoassay (Figure 2, lower panel) methods. On the
basis of the results of these experiments, we chose the antibody
2K1 which efficiently recognizes TF with both methods.
As demonstrated by western blot analysis, TF was present in
homogenates of purified eosinophils from patients with hyper-
osinophilic disorders (Figure 3, panel A). A major band with Mr of
47,000 corresponding to the native TF was found in the eosinophil
homogenates from the 9 patients and the 9 controls. The intensity
of the bands, expressed as the ratio to the band of standard
recombinant TF, was significantly higher in patients with
hypereosinophilic disorders than in normal subjects, median
(range) 1.77 (0.82–2.63) vs 0.49 (0.25–0.75) (p,0.0001) (Figure 3,
panel A and B). As positive control we evaluated TF by western
blot in 2 homogenate samples of purified monocytes, in 2
homogenate samples of purified endothelial cells from line
ECV304 and in 4 homogenate samples of purified fibroblasts
from cell line IMR90 (Figure 3, panel A, bottom).
Figure 3. Panel A shows the western blot analysis of tissue factor (TF) in homogenate samples of purified eosinophils from 9
patients with hyperosinophilic conditions (HE) (top), purified eosinophils from 9 normal controls (N) (middle), and purified
monocytes from 2 normal controls (M), purified endothelial cells from 2 samples of cell line ECV304 and purified fibroblasts from 4
samples of cell line IMR90 (bottom). A major band with Mr of 47,000 corresponding to the native TF was found in the eosinophil homogenates
from the 9 patients and the 9 controls, with a higher intensity in the former than in the latter. The intensity of the TF band was weaker in monocytes
(M1, M2) than in endothelial cells (ECV304) and in fibroblasts (IMR90). Panel B shows the western blot analysis of the ubiquitary protein beta-actin,
which was well represented in all patients, normal subjects and positive controls.
doi:10.1371/journal.pone.0111862.g003
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To rule out the possibility that low levels of TF found in some
samples were due to the reduction of total proteins; in the same
samples, we evaluated by western blot the ubiquitary protein actin,
which was well represented in all patients, normal subjects and
positive controls (Figure 3, panel B).
Evaluation of tissue factor mRNA in isolated eosinophils
Real-time polymerase chain reaction (RT-PCR) analysis
revealed different amplifications in 9 patients with hypereosino-
philia using TF specific sets of primers and probes (Figure 4). As
shown in table 2 and in figure 4, TF cycle threshold was
significantly lower in patients with hypereosinophilia than in
healthy subjects, median (range) 35.10 (19.45–36.50) vs 37.17
(35.33–37.87) (p = 0.002), indicating that TF gene expression was
higher in hypereosinophilic disorders. Interestingly, the two
patients with idiopathic hypereosinophilic syndrome and ischemic
heart attacks, showed the lowest TF cycle threshold (19.45 and
33.68) indicating an enhanced TF gene expression. The cycle
thresholds of the housekeeping gene beta actin in patients and
controls ranged between 27.79 and 36.31, without any significant
differences between the two groups (Table 2). Considering the
beta-actin controls, the relative quantification of PCR data
confirmed a significantly higher expression of TF mRNA in
patients with hypereosinophilia than in normal subjects (Table 2).
We also analyzed TF expression in 4 samples of monocytes,
cycle threshold: median (range) 31.32 (29.82–33.49), correspond-
ing to moderate amount, in 4 samples of endothelial cell line
ECV304, cycle threshold: 28.70 (27.79–29.57), corresponding to
abundant amount, and in 8 samples of fibroblast cell line IMR90,
cycle threshold: 22.77 (19.22–25.05), corresponding to abundant
amount.
Discussion
The results of the present study show that TF is detectable in
high-purity preparations of immunologically isolated eosinophils
from healthy subjects and patients with different hypereosinophilic
conditions. TF gene expression was higher in eosinophils from
patients with hypereosinophilic disorders than in those from
normal subjects (on the basis of RT-PCR cycle threshold). Western
blot analysis revealed that a strong expression of TF by eosinophils
was significantly more frequent in patients with hyperosinophilia.
Figure 4. Panel A shows real-time polymerase chain reaction (RT-PCR) analysis of tissue factor (TF) in purified eosinophils from 9
patients with hyperesinophilia (HE, red lines) and 9 normal controls (N, blue lines). Panel B shows RT-PCR analysis of beta-actin in purified
eosinophils from 9 patients with hyperesinophilia (HE, red lines) and 9 normal controls (N, blue lines). Panel C shows RT-PCR analysis of TF in purified
monocytes from 4 normal controls (green lines), in 4 samples of endothelial cell line ECV304 (blue lines) and in 8 samples of fibroblast cell line IMR90
(red lines). Panel D shows RT-PCR analysis of beta-actin in purified monocytes from 4 normal controls (green lines), in 4 samples of endothelial cell line
ECV304 (blue lines) and in 8 samples of fibroblast cell line IMR90 (red lines).
doi:10.1371/journal.pone.0111862.g004
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Although eosinophil immunoreactivity with antibodies to TF
could be due, at least in part, to internalization and storage of TF
produced by other cells, namely monocytes [22], our data indicate
that eosinophils themselves are able to produce TF in variable
amounts, and TF content seems to be increased in hypereosino-
philic conditions. These observations are in keeping with studies
showing that eosinophils produce, store and rapidly transfer TF to
the cell membrane during activation [5]. However, Sovershaev et
al. [19] have failed to find TF expression by purified blood
eosinophils. Different reasons have been advocated to explain
these discrepancies. Firstly, antibodies used in the immunoassays
may have different sensitivity and specificity in TF detection, as
demonstrated by our results (Figure 2) and by those of Basavaraj et
al. [23]. Secondly, immunochemical detection of TF in eosinophils
may be due to attachment and uptake of monocyte-derived TF, as
demonstrated in granulocytes by Egorina et al. [22]. Finally, the
detection of TF mRNA in purified eosinophils could be due to
non-specific amplification during the late cycles of PCR or
contamination of the eosinophil fraction with monocytes, as
hypothesized by Sovershaev et al. [19]. However, in the present
study this last possibility is unlikely given the high purity of our
eosinophil preparations (Figure 1). In our experiments, we have
compared three different antibodies to TF and we have chosen the
most efficient in TF binding to test blood eosinophils. The
observation that immunoreactivity for TF in purified eosinophils
was variable in different subjects being almost absent in 2 out of 9
normal controls renders unlikely a non-specific binding of the
antibody and supports interindividual differences in TF expres-
sion. In contrast, a strong reactivity was observed in 8 out of 9
patients with hypereosinophilic conditions. We cannot exclude
that part of the TF detected in purified eosinophils is the result of
uptake of monocyte-derived TF; however, the detection of TF
mRNA in purified eosinophils suggests that it is, at least in part,
produced by eosinophils themselves. The very high level of TF
mRNA detected in eosinophils from one patient with idiopathic
hypereosinophilic syndrome indicates that TF production by
eosinophils is variable and can be markedly increased in
pathological conditions. The reasons of the enhanced TF
expression by blood eosinophils from patients with hypereosino-
philia are as yet unknown; however, a candidate effector molecule
may be interleukin-5 (IL-5) due to its pivotal role in promoting
survival and activation of eosinophils [24]. Future studies are
needed to investigate whether stimulation of eosinophils with IL-5
upregulates TF expression.
Previously, we demonstrated by immunohistochemical methods
that TF is expressed by inflammatory cells present in the infiltrate
of chronic urticaria skin lesions [25]. The nature of the TF-
expressing cell was revealed by performing double-staining studies
Table 2. Expression of target (tissue factor) and housekeeping (beta-actin) genes in purified eosinophils obtained from 9 patients
with hypereosinophilia and 9 normal controls.
N Condition Tissue factor Ct Beta-actin Ct 2DCt
Patients with hypereosinophilia
1 Bullous pemphigoid 36.50 31.27 0.43
2 Asthma with eosinophilia 35.20 36.31 2.16
3 Bullous pemphigoid 33.72 31.56 0.45
4 Churg-Strauss syndrome 35.10 31.04 0.51
5 Asthma with eosinophilia 34.91 28.98 0.52
6 Strongyloidiasis 35.67 33.12 0.37
7 Ascariasis 35.54 30.10 0.49
8 Idiopathic hypereosinophilic syndrome 19.45 27.79 20.25
9 Idiopathic hypereosinophilic syndrome 33.68 32.25 0.56
Median 35.10 * 31.27 0.51**
Range 19.45–36.50 27.79–36.31
Normal controls
1 Healthy 37.18 31.66 0.02
2 Healthy 36.04 33.65 0.19
3 Healthy 35.33 33.23 0.23
4 Healthy 37.87 30.47 0.01
5 Healthy 37.25 33.89 0.10
6 Healthy 36.62 31.76 0.03
7 Healthy 37.17 29.57 0.01
8 Healthy 37.23 31.95 0.03
9 Healthy 36.12 30.28 0.02
Median 37.17 31.76 0.03
Range 35.33–37.87 29.57–33.89 0.01–0.23
Gene expression was analysed by real-time polymerase chain reaction and reported as cycle threshold (Ct) and as corrected Ct (2DCt = 2Ct tissue factor - Ct beta actin).
* Median value of tissue factor cycle threshold (Ct) was significantly lower in patients with hypereosinophilia than in healthy subjects (p = 0.002). **Median value of
tissue factor Ct corrected for beta actin Ct (using the equation 2DCt = 2Ct tissue factor - Ct beta actin) was significantly higher in patients with hypereosinophilia than in healthy
subjects (p = 0.0001). Both analyses indicate an increased mRNA espression of tissue factor in patients with hypereosinophilia.
doi:10.1371/journal.pone.0111862.t002
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that showed co-localization of TF and eosinophil cationic protein,
a classic cell marker of the eosinophil [26]. The strong expression
of TF in chronic urticaria lesional skin may be due to eosinophil
activation, even if patients with chronic urticaria virtually never
show peripheral eosinophilia, probably because TF specifically
facilitates the early transendothelial migration of the eosinophils
[5]. Further immunohistochemical studies, carried out in patients
with bullous pemphigoid, an autoimmune blistering disease
characterized by skin and peripheral blood eosinophilia, showed
a strong TF expression in lesional skin [27]. Immunofluorescence
studies using laser scanning confocal microscopy showed that, in
patients with bullous pemphigoid, most of the cells making up the
inflammatory infiltrate co-expressed TF and the eosinophil marker
CD125, thus indicating that they were eosinophils [27,28].
Considering that TF is the main activator of blood coagulation,
the demonstration that eosinophils produce and store TF raises the
possibility that they are involved in coagulation activation. Thus,
they may contribute to induce thrombosis, even if other
eosinophil-related pathophysiologic mechanisms may be operat-
ing, including endothelium damage and platelet activation.
Eosinophils may damage endothelial cells by releasing peroxidase,
and stimulate platelet activation and aggregation through several
additional proteins contained in their granules, such as eosinophil
cationic protein and major basic protein [14,15]. Furthermore,
eosinophils express CD40 ligand, which is involved in initiation
and progression of thrombosis through amplification of the
inflammatory network [16,17]. Finally, platelet activating factor
(PAF), a lipid mediator generated after eosinophil stimulation [18],
induces the activation of platelets, leukocytes and endothelial cells.
It would be interesting to determine if the increase of TF observed
in eosinophils of patients with hypereosinophilia occurs primarily
inside the cell or at transmembrane level. The latter possibility
could be relevant to the increase of thrombotic risk due to the
interaction of transmembrane TF with the other blood compo-
nents. Our results do not allow to distinguish between intracellular
and transmembrane TF since the antibody used recognizes the
extracellular domain of TF which is shared by the two forms.
Thus, to define the subcellular localization of TF in hypereosino-
philic conditions further methods are needed using the approach
of Moosbauer et al. with electronic microscopy [5] or that of
Mandal et al. and Pen˜a et al. with confocal microscopy [29,30].
Some hypereosinophilic conditions such as idiopathic hyper-
eosinophilic syndrome, Churg-Strauss syndrome and bullous
pemphigoid are characterized by an increased incidence of
thrombotic events [9,10,31,32]. It is conceivable that TF
expression by eosinophils has an important role in increasing the
thrombotic risk of patients with hypereosinophilic conditions.
Although the amount of TF generated by and stored in peripheral
blood eosinophils is variable and may be small or moderate
compared to other cell types (i.e. monocytes and endothelial cells),
the presence of large numbers of eosinophils in hypereosinophilic
conditions may markedly amplify the TF effect on coagulation.
The observation that two of our patients with idiopathic
hypereosinophilic syndrome experienced ischemic heart attacks,
healed after steroid-induced normalization of the eosinophil count,
further supports a link between eosinophils and cardiovascular
events.
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